MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/ijem.ijem_1075_25

Медицинская библиотека · Indian journal of endocrinology and metabolism · 2026

Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre.

Dash Bandana, Ravi Kumar Padala, Dash Deepak K, Patro Debasish, Sahu Pradosh K, Rao Mandapaka V K

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 2 diabetes mellitus (T2DM). This study evaluated the effect of dapagliflozin on liver fat, liver stiffness, and visceral adiposity in patients with T2DM and MASLD.

METHODS

This was a single-arm, prospective, open-label interventional study with a paired design. Sixty-three patients with T2DM and moderate-to-severe hepatic steatosis on ultrasonography received dapagliflozin 10 mg daily for six months. Liver fat by dual-echo-magnetic resonance imaging (MRI), liver stiffness measurement (LSM) by fibroscan, and visceral adipose tissue (VAT) by dual X-ray absorptiometry were assessed at baseline and after six months. Response to therapy was defined as >10% decrease in liver fat and >15% decrease in LSM, respectively (Responders). Multivariable logistic regression analysis was performed to identify predictors of response with respect to change in liver fat and LSM.

RESULTS

After six months, mean weight decreased by 2.55 kg (3.23%) and HbA1c by 0.84%. MRI-liver fat percentage, LSM, and VAT volume declined by 2.7%, 0.85kPa, and 472 cm3, respectively (P < 0.001 for all). Change in VAT mass (r = 0.546) and volume (r = 0.437) correlated with change in liver fat, and change in aspartate aminotransferase (AST) correlated with change in LSM (r = 0.351). Sixteen patients (25.4%) and 33 patients (52.4%) met the criteria for responders for liver fat and LSM, respectively. Baseline liver fat and LSM were independent predictors of decrease in liver fat and LSM, respectively in responders.

CONCLUSION

Dapagliflozin significantly reduced liver fat, liver stiffness, and visceral adiposity in patients with T2DM and MASLD.

Для цитирования: Dash Bandana, Ravi Kumar Padala, Dash Deepak K, Patro Debasish, Sahu Pradosh K, Rao Mandapaka V K. Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre.. Indian journal of endocrinology and metabolism. 2026. DOI: 10.4103/ijem.ijem_1075_25.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.